Menu
Washingtoner
  • Home
  • Business
  • Real Estate
  • Technology
  • Home
  • Health
  • Self Storage
  • Pets
  • Security
Washingtoner

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
Washingtoner/10237740

Trending...
  • InventHelp Inventor Develops New Accessory for Fishermen (TGR-242)
  • Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
  • myb.day Launches New Birthday Gift Shop Filled With Personalized Surprises
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had "high-risk" TA-TMA. Narsoplimab is Omeros' investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. The report was authored by an external group of investigators involved in the treatment of these patients with narsoplimab provided under Omeros' compassionate use program.

The report will be featured as a poster presentation at the 65th Annual Meeting of the American Society of Hematology (ASH), to be held December 9-12, 2023 in San Diego. The abstract (#3543) is available on the ASH website at www.hematology.org or by clicking here.

The poster will be presented by Dr. Marta Castelli, Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. Details of the presentation are as follows:

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience (Abstract #3543)
Session Name: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Date: Sunday, December 10, 2023
Presentation Time: 6:00 p.m. - 8:00 p.m. PT

More on Washingtoner
  • ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
  • Pathways to Adulthood Conference May 17 at Melville Marriott Honoring NYS Assembly Member Jodi Giglio, Suffolk County Legislator Nick Caracappa
  • Adster Techologies awarded US Patent for breakthrough innovation in reducing latency in Ad Serving
  • Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio

Location: San Diego Convention Center, Halls G-H

About Narsoplimab

Narsoplimab, also known as "OMS721," is an investigational fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 has been demonstrated to leave intact the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. A biologics license application (BLA) is pending before the U.S. FDA for use of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), and Omeros expects to resubmit the BLA to include additional information supporting approval of narsoplimab in this indication. Narsoplimab is also in clinical development programs focused on other complement-mediated disorders, including COVID-19. FDA has granted narsoplimab breakthrough therapy and orphan drug designations for TA-TMA and orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies as well as for the treatment of TA-TMA. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 multi-ascending dose clinical trial. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder and, in addition, is being developed as a therapeutic for other addictions as well as for a major complication of treatment for movement disorders. Omeros also is advancing a broad portfolio of novel immuno-oncology programs comprised of two cellular and three molecular platforms. For more information about Omeros and its programs, visit www.omeros.com

More on Washingtoner
  • L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
  • Spokane: Flags Lowered for Justice Owens
  • Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
  • Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
  • Space Resources Company Interlune Unveils Full-Scale Prototype of Excavator for Harvesting Helium-3 from the Moon

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "expect," "intend," and similar expressions and variations thereof. Forward-looking statements, including statements regarding Omeros' investigational drug candidates, anticipated next steps in relation to the biologics license application for narsoplimab or in relation to other development programs are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unanticipated or unexpected outcomes of regulatory processes in relevant jurisdictions, unproven preclinical and clinical development activities, the Company's financial condition and results of operations, regulatory processes and oversight, challenges associated with manufacture or supply of our investigational or clinical products, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2023. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contacts

Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
IR@omeros.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • NASDAQ Uplisting for Higher Market Exposure and Wide Corporate Benefits to AI Boosted Marketing Company On Track Towards $1 Billion Revenue by 2027
  • Congressional Men's Health Caucus Shows Bipartisan Consensus and Focus on Prevention, Mental Health, and Closing the Lifespan Gap
  • DuoKey, Axiomtek and Blue Edge Network Partner to Enhance Smart Cities with Privacy-Preserving Urban Safeguarding and Fleet Management
  • PNNL's Grid Storage Launchpad honored with 2025 BCI Innovation Award
  • Austin Keen Joins WakeFX RopePal as Official Brand Ambassador
  • Bonelli Systems Expands Managed IT Services Nationwide, Leveraging Microsoft Azure Expertise
  • $4.3 Million Patent Application Waiver Fee Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression & PTSD: NRX Pharma
  • Whistleblower Claims Dental Patient Deaths Likely Due to Book Ban
  • xREnergy up as much as +3,094,634% on first day listed on the XRP Ledger. Ticker : $XRE
  • Psychiatry's Legacy of Racism and Coercion Highlighted in Restraint Deaths
  • New Book 'Cybersecurity Leadership' Guides SME Leaders to Make Smart, Strategic Security Decisions
  • "Stop scrolling and start watching" - Beloved film recommendation site Criticker gets a major makeover
  • Green Energy Solar Expands with New Offices in Port St. Lucie, West Palm Beach, and Orlando
  • IGT PlaySports Introduces World-Class Retail Sports Betting to Silver Reef Casino Resort
  • Events by Dubsdread Expands Services to The Venue at Lake Lily
  • London Gala Emphasizes Trade, FDI and Ongoing Cooperation
  • Sahit Muja Launches Trillion-Dollar Green Revolution with 10 Groundbreaking Cryptos
  • Free and Low-Cost Dental Care Now Available in London Through the Canadian Dental Care Plan (CDCP)
  • Garden State Gay Socials Turns One: 1st Birthday Celebration for Gay Men Who Want Real Connection
  • Sea Fox® 368X "Extreme Edition" by Black Label Marine Group Celebrates 5 Years of the Commander Legacy
_catLbl0 _catLbl1

Popular on Washingtoner

  • 11th annual Florida Blueberry Festival April 26 & 27, 2025 - 142
  • HR Tech Awards Program Celebrates 6th Year: Showcases Top Hiring, Talent, and HR Technologies - 122
  • People & Stories/Gente y Cuentos Announces New Board Leadership & Corporate Partnership Initiative - 114
  • Mission 3A Establishes Healthcare Advisory Board with Addition of Industry Leaders Patrick Fisher, Kevin Cordell, and Dr. Greg Berlet - 111
  • American Mensa Welcomes 7-Year-Old Savannah Boy - 110
  • PebblePad Welcomes Justin Reilly as New CEO to Drive Innovation and Growth - 109
  • Village Vapes and Cooking 4 Autism Announce Inaugural Partnership at MEGA 420 EVENT
  • Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit
  • S2C and Andes Technology Announce FPGA-Based Prototyping Partnership to Accelerate Advanced RISC-V SoC Development
  • The Great Junk Hunt Returns to Puyallup – A Vintage Shopping Experience Like No Other!

Similar on Washingtoner

  • NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
  • Beaches and Big Cities Remain the Top Travel Destination for American Summer Travelers
  • Cybersecurity is Protecting Your Personal Information and Your Portfolio
  • Space Resources Company Interlune Unveils Full-Scale Prototype of Excavator for Harvesting Helium-3 from the Moon
  • The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
  • $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
  • SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
  • Ditch Micromanagement: New Leadership Book for Results-Driven, Accountability-Based Teams
  • Jay Tapp was named Managing Director in British Columbia
  • 20 Patents Issued Worldwide, Cementing Company Leadership. First Ever Cable-Free 12-Lead ECG: HeartBeam, Inc. (Stock Symbol: BEAT)
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute